Calcimax D3

Quick links to important sections

Calcimax D3

Method of action: Vitamins

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calcimax D3

Calcimax D3 is a combination medicine classified fundamentally as a nutritional supplement that integrates an essential mineral with a calcium regulatory agent. It is designed for administration via the oral route to support the body's mineral homeostasis and bone health.

Property Description
Active ingredient Calcium Citrate, Dihydrotachysterol (DHT)
Form Tablet, Oral Solution, Suspension
Pharmacological class Mineral Supplements, Vitamin D and Analogues
Common use Supporting bone health, addressing nutritional deficiencies
Origin Mineral (Calcium Citrate), Synthetic (DHT)

What is Calcimax D3 and Its Pharmacological Classification?

Calcimax D3 is a combination product categorized within the pharmacological classes of Mineral Supplements and Vitamin D and Analogues. This classification, which is recognized in international therapeutic systems, signifies its dual role: supplying a vital building block and facilitating its utilization. The preparation is consistently manufactured for administration via the oral route and is available in common dosage forms, including the solid tablet and the liquid oral solution or suspension. The product is clinically recognized for its systematic approach to mineral regulation.

The Active Composition: Calcium Citrate and Dihydrotachysterol

The core of Calcimax D3 consists of Calcium Citrate and Dihydrotachysterol (DHT). Calcium Citrate is a specific organic calcium salt chosen to provide bioavailable elemental calcium. Dihydrotachysterol is a potent, synthetic analog of Vitamin D. This class of compounds is used in the regulation of calcium and phosphate metabolism.

The fact that Dihydrotachysterol is a synthetic analog is a distinctive feature, as it bypasses certain metabolic steps, allowing it to act as an efficient calcium regulator. This specific combination is often positioned for patients requiring reliable mineral management, such as those needing proactive skeletal support.

General Purpose: Support for Mineral Balance

The overall purpose of Calcimax D3 is to efficiently support systemic mineral homeostasis and effective calcium regulation, which directly contributes to the maintenance of the structural integrity of the skeletal system. The preparation is intended to address and manage nutritional deficiencies related to these core components. A typical use scenario involves providing foundational support for bone health in adults.

Regulatory References

  1. Calcium and Phosphate Homeostasis - Endotext - NIH

What side effects are possible with Calcimax D3?

Possible Side Effects and Safety Information

The primary safety concern associated with this combination product (Calcium Citrate and Dihydrotachysterol) is the potential for Hypercalcemia (abnormally high calcium levels in the blood) and Hypercalciuria (excessive calcium excretion in the urine), which are dose- and duration-dependent. This is the central risk driving the officially documented safety profile.

Adverse reactions officially listed in regulatory documents are generally manifestations of elevated calcium and may be grouped by the physiological systems they affect:

  • Gastrointestinal Disorders: These effects may include Nausea, Vomiting, Constipation, and Dry Mouth.
  • Nervous System Disorders: Reactions documented in this system include Headache, Weakness, and Drowsiness.
  • Renal and Urinary Disorders: Sustained elevation of calcium can lead to Polyuria and serious adverse reactions involving the kidneys.

Serious Adverse Reactions officially documented are the severe outcomes of uncontrolled calcium excess. These include the development of Nephrocalcinosis (calcium deposits in renal tissue), Renal Impairment or Failure, generalized Soft Tissue Calcification, and disturbances in heart rhythm known as Cardiac Arrhythmias. These are typically associated with cumulative overdosage and long-term exposure rather than acute events.

Regulatory documents define specific Safety Constraints and contraindications. The product is not for use in individuals with known hypercalcemia or documented Vitamin D toxicity. Caution is explicitly stated for patients with Impaired Renal Function or Hyperphosphatemia, as these conditions heighten the safety risk.

Overdose and Emergency Response

Calcimax D3 overdose is defined by Hypercalcemia and Hypercalciuria, which result from the toxic effects of the Vitamin D analog, Dihydrotachysterol, combined with the presence of supplemental calcium. Official regulatory sources document manifestations beginning with general gastrointestinal and systemic symptoms, including nausea, vomiting, fatigue, abdominal cramps, and excessive thirst (polydipsia) or urination (polyuria).


Severe overdose can rapidly progress to life-threatening outcomes. Documented complications include severe cardiac arrhythmias, renal insufficiency potentially leading to kidney failure, and widespread, permanent soft tissue calcification. Central nervous system effects such as confusion, stupor, or coma may also occur. Immediate medical attention must be sought if severe symptoms are present.


The regulator-mandated first action is the immediate withdrawal and discontinuation of the product and all supplemental calcium. No specific chemical antidote is known; management is symptomatic and supportive, typically involving intravenous hydration and continuous blood calcium monitoring until normalization. Specific overdose caution is noted for pregnancy, as prolonged hypercalcemia carries the risk of documented fetal abnormalities, including mental and physical retardation.

Therapeutic Uses of Calcimax D3

Calcimax D3 is a combined calcium and Vitamin D supplement, applied across domains where additional symptomatic support for musculoskeletal and systemic well-being is needed, particularly when related to known deficiencies.

The combination is commonly used along with calcium to prevent and manage bone diseases. This medication is relevant for easing symptoms associated with osteoporosis, osteomalacia, and certain patterns of muscle cramps or latent tetany.


Supporting Bone Strength and Functional Stability

This block is commonly used to help with conditions where functional stability becomes affected, such as weakened bone structure. The supportive relief helps address symptom clusters that may become intense, which contributes to easing the overall symptom burden. It is commonly used to help support general well-being during symptomatic phases.

“This supportive therapy helps maintain a sense of stability when symptoms are more noticeable.”


Easing Musculoskeletal Symptoms and Systemic Strain

Calcimax D3 is applied across domains where additional symptomatic support is needed, often in clinical scenarios involving heightened physiological stress, such as during pregnancy, post-menopause, or periods of specific nutritional deficiency. It supports patients during episodes of heightened discomfort and is relevant when symptoms related to physical discomfort interfere with daily functioning.


Quick Fact: Symptom Management
May assist with stability during episodes of muscle cramps and discomfort linked to low calcium levels.

Regulatory References

  1. NIH MedlinePlus Drug Information on Cholecalciferol (Vitamin D3)

Eligibility and Restrictions for Use

Who Can and Cannot Use Calcimax D3?

The eligibility for Calcimax D3 (Calcium Citrate and Dihydrotachysterol) is determined by strict regulatory criteria focusing on the patient's existing metabolic status and organ function, as defined in official prescribing information.


Absolute Contraindications

Use of this medicine is strictly prohibited for patients with pre-existing Hypercalcemia (abnormally high blood calcium levels) or Hypervitaminosis D (excessive vitamin D levels). It is also contraindicated for individuals with known hypersensitivity to any component of the preparation. Regulatory documents state that this medicine is contraindicated in breast-feeding mothers.


Conditional Use and Restrictions

Specific populations require strict caution and conditional use. Individuals with Severe Renal Impairment are restricted due to the heightened risk of developing hypercalcemia. Caution is also necessary for patients with a history of renal stones or conditions such as Sarcoidosis, which may increase sensitivity to Vitamin D effects. For pregnancy, use is conditional and only permitted if the potential benefit outweighs the possible risk to the fetus.


Age-Related Eligibility

While the medicine is typically used in adults for indicated conditions, its safety and effectiveness are not established in all pediatric age groups, and dosage must be highly individualized. Dose selection for older adults requires caution and monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Calcimax D3 (Calcium Citrate and Dihydrotachysterol) defines interaction profiles based on two major concerns: altered drug exposure and potentiated mineral effects.

Interactions Affecting Drug Exposure (Timing Rules)

  • Tetracycline and Quinolone Antibiotics: Calcium Citrate reduces the systemic exposure of these antibiotics by forming insoluble complexes in the gut. Regulatory labels require a separation of administration time between Calcimax D3 and antibiotics like ciprofloxacin or doxycycline.
  • Bisphosphonates and Thyroid Hormones: The absorption and resulting efficacy of bisphosphonates (e.g., alendronate) and levothyroxine are compromised by co-administration with calcium. Dosing time must be separated as per official instructions.
  • Bile Acid Sequestrants: These agents can decrease the absorption of the fat-soluble Dihydrotachysterol component.

Interactions Affecting Mineral Balance (Pharmacodynamic Risk)

  • Contraindicated Combination: Co-administration with other Vitamin D analogs or high-dose Vitamin D products is associated with an elevated risk of additive hypercalcemia and potential toxicity.
  • Cardiac Glycosides (e.g., Digoxin): The risk or severity of ventricular arrhythmias is increased due to the potentiation of cardiotoxic effects in the presence of hypercalcemia, which is a documented interaction outcome.
  • Thiazide Diuretics: Co-administration with diuretics, such as chlorothiazide, decreases the renal clearance of calcium, resulting in an increased risk of hypercalcemia.

Special Population Notes

  • Patients with renal impairment face a greater risk of hypercalcemia and calcium-phosphate deposits due to altered absorption and clearance. Patients with hepatic impairment may experience altered metabolic activity of Dihydrotachysterol.

Mechanism of Action

Coordinated Regulation of Mineral Homeostasis

The mechanism of Calcimax D3 is defined by the synergistic action of a calcium substrate (Calcium Citrate) and a synthetic regulator (Dihydrotachysterol, DHT). DHT acts as an agonist for the nuclear Vitamin D Receptor (VDR), initiating a gene-transcription cascade that affects mineral uptake and conservation. Simultaneously, the elemental calcium activates the Calcium-Sensing Receptor (CaSR) on the parathyroid glands.


Increasing Systemic Mineral Flux and Retention

This coordinated agonism suppresses the release of Parathyroid Hormone (PTH), a major bone-resorptive signal. This suppression, alongside VDR-mediated upregulation of calcium channels ( TRPV6) in the intestine and kidney, creates a net increase in systemic mineral content. The mechanism alters the flux of calcium across epithelial barriers, increasing systemic availability and modulates the activity of the skeletal remodeling cycle.


Distinctive Pharmacodynamic Profile

The specific use of Dihydrotachysterol grants the mechanism a distinct regulatory profile, as it bypasses a final metabolic hydroxylation step in the kidney required by native Vitamin D3. This allows for a more rapid VDR agonism and coupling of substrate supply with regulatory signals.

Dosage and Administration Information

How to Use Calcimax D3: Administration Guidelines

Calcimax D3, a combination of Calcium Citrate and Dihydrotachysterol (DHT), is administered based on established guidelines. The primary goal of these descriptions is to define the usage pattern for maintaining mineral balance, without providing individual medical advice.


Administration Scope

The preparation is exclusively intended for the oral route of administration. It is available in common dosage forms, including tablets and oral liquid forms, such as solutions or suspensions.

Instruction Detail
Dosing Schedule Highly individualized, based on serum calcium/phosphate levels. Maintenance dose for Dihydrotachysterol (DHT) is typically in the range of 0.2 mg to 1.0 mg daily. Adequate concurrent elemental calcium intake is mandated (e.g., 500 mg to 1500 mg/day).
Frequency Pattern Typically administered once daily, although a schedule of divided doses may be used to enhance calcium absorption.
Timing in Relation to Meals Administration is generally specified as with meals or shortly after food intake to optimize the drug's absorption profile.
Preparation Requirements Liquid forms (solutions or suspensions) must be shaken well immediately prior to measurement and use to ensure proper dose homogeneity.

Usage Protocol and Population Rules

It is established that Calcimax D3 is intended for long-term, continuous support. Any necessary dose adjustments of Dihydrotachysterol require careful clinical oversight and must be implemented slowly—generally with intervals of not less than four to eight weeks—to allow for stable serum calcium level monitoring. For patients with impaired renal or hepatic function, dose monitoring is intensified due to the altered metabolism of the vitamin D analog component.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Calcimax D3

The research landscape for Calcimax D3 (a combination of Calcium Citrate and Dihydrotachysterol) primarily involves studies that explore how these components, individually and together, affect mineral and bone health. The goal of this overview is to describe what has been examined in clinical research, what has been observed in those study settings, and what questions still remain, according to official and peer-reviewed sources.


Evidence for Use in Skeletal Support

Research into the use of this combination for skeletal support, particularly in conditions involving bone loss, has largely relied on Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. Calcimax D3 was studied for use in contexts related to postmenopausal osteoporosis. Studies monitored specific patient-reported outcomes describing perceived discomfort, such as measuring the Bone Mineral Density (BMD) at the hip and spine. Researchers also monitored outcomes describing episodic or acute changes over time. Findings from these long-term studies, which involved postmenopausal women and extended up to seven years, were sometimes mixed when examining outcomes related to systemic or functional imbalance.


Evidence for Use in Mineral Regulation

Research examined the combination's role in addressing conditions where systemic or functional imbalance in minerals is present, notably for Vitamin D insufficiency or low dietary calcium intake. The studies were primarily RCTs and observational settings. These research settings monitored shifts in key laboratory measurements (biomarkers), specifically 25(OH)D (Vitamin D) and parathyroid hormone (PTH). Findings describe patterns observed in the studies where participants receiving the supplement showed changes in these levels. The data show patterns related to changes measured during the study period in blood calcium and phosphate concentrations in the observed populations.


What Remains Uncertain and Research Gaps

It is essential to understand that the evidence for Calcimax D3 is limited in certain areas. Long-term effects are not fully established regarding the sustained patterns related to BMD beyond the periods of active study follow-up. Furthermore, comparative evidence is lacking between the Dihydrotachysterol combination and other forms of Vitamin D and calcium in large, dedicated trials. The research provides context but not individual predictions, and data for certain groups remain insufficient, particularly in long-term observational settings.

Key Studies & References

  1. Hypoparathyroidism - StatPearls (Calcium and Vitamin D Supplementation)

Frequently Asked Questions (FAQ)

Common questions about Calcimax D3 (FAQ)


Q: Is Calcimax D3 a prescription medicine or is it available over the counter?

Calcimax D3 contains Dihydrotachysterol (DHT), which is classified as a potent synthetic Vitamin D analog. Products containing potent analogs typically require a prescription and strict medical monitoring. The potential for serious mineral imbalances associated with potent analogs generally leads to the requirement of clinical monitoring.


Q: How does Calcimax D3 differ from standard calcium supplements?

The key difference lies in the specific Vitamin D component. Standard calcium supplements often use native Vitamin D, while Calcimax D3 contains the synthetic analog Dihydrotachysterol (DHT). According to official mechanism descriptions, DHT is designed to act more directly as a calcium regulator, bypassing a metabolic activation step that is typically required in the kidneys.


Q: What is the difference between Calcimax D3 and other similar combination products?

Similar combination products may use native Vitamin D3 (cholecalciferol) or other analogs. Calcimax D3's distinction is its use of Dihydrotachysterol (DHT), which gives it a specific metabolic profile. Products with different Vitamin D components may have different regulatory rules for monitoring and administration.


Q: Can taking Calcimax D3 affect the absorption of other medications?

Yes. Regulatory documents state that the calcium component can interfere with the absorption and effectiveness of certain other medicines. This includes some antibiotics (like tetracyclines), bisphosphonates, and thyroid hormones. Official regulatory labels specify that these medications be taken at a separate time.


Q: Is it necessary to separate the time when I take Calcimax D3 from when I take thyroid medication?

Yes, official instructions clearly state that calcium-containing products should be separated from thyroid hormone medicines, such as levothyroxine. This separation is required because co-administration can compromise the absorption and resulting effectiveness of the thyroid medication.


Q: What happens if I miss a dose of Calcimax D3?

Regulatory labels generally advise that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Regulatory documents state that doubling the dose is not recommended.


Q: Is it possible for Calcimax D3 to cause an allergic reaction?

Yes, it is possible. Official regulatory documents list hypersensitivity (severe allergic reaction) to any component of the product as an absolute contraindication. Hypersensitivity is the medical term for a severe allergic reaction.


Q: Does Calcimax D3 contain any sugar or gluten?

The presence of inactive ingredients like sugar or gluten depends on the specific formulation of the product, such as whether it is a tablet or an oral solution. Regulatory labels list all inactive components, and the patient is advised to consult the label for specific dietary needs.


Q: Does Calcimax D3 contain Vitamin K?

Official labeling lists the active ingredients of Calcimax D3 as Calcium Citrate and Dihydrotachysterol (DHT). Vitamin K is not listed as an active component in this specific combination product.


Q: Why is it important to check Vitamin D levels before starting Calcimax D3?

Checking mineral levels is typically performed because the medicine is contraindicated in certain states of excess. This is important because the medicine must not be used in people who already have Hypervitaminosis D (excessive Vitamin D) or Hypercalcemia (abnormally high calcium levels).


Q: Why do people say Calcimax D3 is for bone health?

It is officially associated with bone health because the combination of calcium and the Vitamin D analog is used to support systemic mineral balance. This balance is crucial for the efficient regulation and maintenance of the structural integrity of the skeletal system, according to pharmacological classifications.


Q: Is Calcimax D3 the same as Calcitriol?

No. Calcimax D3 contains Dihydrotachysterol (DHT), which is classified as a synthetic Vitamin D analog. Calcitriol is the fully active, natural form of Vitamin D. Although both compounds are utilized to regulate calcium, they are chemically distinct substances.


Q: Can Calcimax D3 cause stomach upset or digestive issues?

Yes. Regulatory documents list various gastrointestinal issues as possible adverse reactions. These reactions may include common symptoms such as nausea, vomiting, constipation, or dry mouth.


Q: Are there any known food or drink restrictions when using Calcimax D3?

Official regulatory warnings advise patients to avoid abrupt changes in their regular dietary intake of foods high in calcium, phosphorus, and Vitamin D. This precaution is necessary to minimize the potential risk of developing a mineral imbalance.


Q: Is Calcimax D3 appropriate for older adults?

Regulatory guidance states that use in older adults requires caution and monitoring. Dose selection is highly individualized, and regulatory guidance focuses on the patient's existing metabolic status and organ function.


Q: Does Calcimax D3 interfere with blood tests?

Since the product delivers high levels of calcium into the system, it may affect the results of certain blood tests that measure mineral levels. This may potentially lead to readings that are elevated or inaccurate for calcium.


Q: Does the time of day matter when taking Calcimax D3?

Official instructions specify that the medicine is generally taken with meals or shortly after food intake to optimize its absorption. Regulatory labels do not typically specify morning versus evening administration.


Q: Are there any known interactions between Calcimax D3 and alcohol?

Official regulatory documents do not typically list a direct interaction warning between alcohol and the active components. However, alcohol consumption may affect nutrient metabolism and overall bone health, which could potentially alter the medicine's effect.


Q: Why do some people experience constipation with Calcimax D3?

Constipation is a documented side effect of this medication. This is generally related to the pharmacological way that calcium supplements interact with the gastrointestinal tract and may affect bowel movement.


Q: Can Calcimax D3 be taken at the same time as iron supplements?

No. Regulatory and nutritional guidance advises against taking them together. Calcium supplements may decrease the absorption of iron, so it is typically recommended that iron and calcium products be taken at separate times.


Q: Is it normal to feel thirsty after taking Calcimax D3?

Thirst is not listed as a common adverse reaction itself in regulatory documents. However, increased thirst is a recognized symptom of Hypercalcemia (abnormally high blood calcium levels), which is the most serious potential risk of this class of medicine.


Q: Can Calcimax D3 affect blood sugar levels?

While treating diabetes is not a primary indication, limited research has investigated the relationship between calcium and Vitamin D supplementation and metabolic markers, including blood sugar levels. Definitive, regulatory claims regarding this effect are not established.


Q: Is Calcimax D3 used to manage Vitamin D deficiency?

Yes. The product is categorized as a Vitamin D analog and a mineral supplement, and official product information states that its common use is to address nutritional deficiencies related to these core components.


Q: What kind of studies support the use of Calcimax D3?

Research supporting the components of Calcimax D3 includes studies such as Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies, often alongside observations in clinical settings, examine the product's effect on mineral and bone health.

How should Calcimax D3 be stored and disposed of?

How to Store and Dispose of Calcimax D3?

Regulatory documents specify strict conditions for storing combination products like Calcimax D3 to protect the stability of its calcium and Vitamin D components.


Official Storage Requirements

Condition
Temperature: Store at room temperature, away from excess heat and moisture.
Protection: The product must be protected from light and humidity.
Container: Keep the medicine in its original container and ensure it is tightly closed.
Child Safety: Store the product out of the sight and reach of children.

Disposal Instructions

Unused or expired medicine must be disposed of according to local and national regulatory guidelines for pharmaceutical waste. Do not flush the medication down the toilet or pour it into a drain to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calcimax D3 found in:

A-Z Index: